

Genetics in Diabetes
Type 2 Diabetes and Related Traits

Frontiers in Diabetes

Vol. 23

Series Editors

M. Porta Turin

F.M. Matschinsky Philadelphia, Pa.



Genetics in Diabetes

Type 2 Diabetes and Related Traits

Volume Editors

Anna L. Gloyn Oxford

Mark I. McCarthy Oxford

27 figures, 7 in color and 14 tables, 2014

KARGER Basel · Freiburg · Paris · London · New York · Chennai · New Delhi ·
Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney

Frontiers in Diabetes

Founded 1981 by F. Belfiore, Catania

Anna L. Gloyn, DPhil

Oxford Centre for Diabetes,
Endocrinology & Metabolism
Churchill Hospital
Headington
Oxford
UK

Mark I. McCarthy, MD, FRCP, FMedSci

Oxford Centre for Diabetes,
Endocrinology & Metabolism
Churchill Hospital
Headington
Oxford
UK

Library of Congress Cataloging-in-Publication Data

Genetics in diabetes : type 2 diabetes and related traits / volume editors,
Anna L. Gloyn, Mark I. McCarthy.

p. ; cm. -- (Frontiers in diabetes, ISSN 0251-5342 ; vol. 23)

Includes bibliographical references and indexes.

ISBN 978-3-318-02699-3 (alk. paper) -- ISBN 978-3-318-02700-6 (e-ISBN)

I. Gloyn, Anna L., editor. II. McCarthy, Mark I., editor. III. Series:

Frontiers in diabetes ; v. 23. 0251-5342

[DNLM: 1. Diabetes Mellitus, Type 2--genetics. 2. Diabetes Mellitus,

Type 2--metabolism. 3. Genome-Wide Association Study--methods. W1 FR945X

v. 23 2014 / WK 810]

RC662.18

616.4'624042--dc23

2014016091

Bibliographic Indices. This publication is listed in bibliographic services.

Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 2014 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)

www.karger.com

Printed in Germany on acid-free and non-aging paper (ISO 9706) by Kraft Druck GmbH, Ettlingen

ISSN 0251-5342

e-ISSN 1662-2995

ISBN 978-3-318-02699-3

e-ISBN 978-3-318-02700-6

Contents

VII Preface

Gloyn, A.L.; McCarthy, M.I. (Oxford)

Gene Discovery Efforts for Type 2 Diabetes

1 **Genome-Wide Association Studies in Type 2 Diabetes**

Beer, N.L.; McCarthy, M.I. (Oxford)

14 **Fine Mapping Type 2 Diabetes Susceptibility Loci**

Morris, A.P. (Oxford/Liverpool)

29 **Whole Genome and Exome Sequencing of Type 2 Diabetes**

Gaulton, K. (Oxford); Flannick, J. (Cambridge, Mass.); Fuchsberger, C. (Ann Arbor, Mich.)

Gene Discovery Efforts for Glycaemic and Metabolic Traits

42 **Genome-Wide Association Studies of Glycaemic Traits: A MAGICal Journey**

Florez, J.C. (Cambridge, Mass./Boston, Mass.); Barroso, I. (Hinxton/Cambridge)

58 **Genome-Wide Association Studies of Obesity and Related Traits**

Mohlke, K.L. (Chapel Hill, N.C.); Lindgren, C.M. (Oxford)

Gene Discovery Efforts for Monogenic Disorders of β -Cell Dysfunction and Insulin Resistance

71 **Next-Generation Sequencing for the Diagnosis of Monogenic Diabetes and Discovery of Novel Aetiologies**

Ellard, S.; De Franco, E. (Exeter)

87 **Whole-Exome Sequencing of Patients with Severe Disorders of Insulin Action**

Semple, R. (Cambridge); Barroso, I. (Hinxton/Cambridge)

'Omics' of Type 2 Diabetes and Related Traits

102 **Epigenetic Modifications and Type 2 Diabetes in Humans**

Ling, C. (Malmö)

111 **Insights into β -Cell Biology and Type 2 Diabetes Pathogenesis from Studies of the Islet Transcriptome**

van de Bunt, M. (Oxford); Morán, I.; Ferrer, J. (London/Barcelona); McCarthy, M.I. (Oxford)

122 **Genomics of Adipose Tissue**

Pinnick, K.E.; Karpe, F. (Oxford)

Insights into Molecular Mechanisms and Pathophysiology from Genetics

133 Translating Genetic Association Signals for Diabetes and Metabolic Traits into Molecular Mechanisms for Disease

Rees, M.G. (Oxford/Bethesda, Md.); Gloyn, A.L. (Oxford)

146 Understanding Molecular Mechanisms for Diabetes and Obesity through Mouse Models

Merkestein, M. (Oxford); Cox, R. (Harwell); Ashcroft, F. (Oxford)

Clinical Translation

158 Genetics of Drug Response in Diabetes

Pearson, E.R. (Dundee); Florez, J.C. (Boston, Mass./Cambridge, Mass.)

173 Translating Advances in Our Understanding of the Genetics of Diabetes into the Clinic

Gardner, D.S. (Oxford/Singapore); Owen, K.R.; Gloyn, A.L. (Oxford)

187 Author Index

188 Subject Index

Preface

In the 1960s, the American Geneticist J.V. Neel referred to diabetes as the ‘geneticists nightmare’ owing to the high probability that the phenotype was heterogeneous, not clearly defined with a variable age of onset and a strong environmental influence. In the 1970s, the distinction between autoimmune (type 1 diabetes) and non-autoimmune (type 2 diabetes) was made clarifying a major cause of the disease heterogeneity. Through the 1990s, the discovery of the genes involved in mendelian forms of diabetes demonstrated the enormous power of human genetics to uncover fundamental insights into glucose homeostasis and to inform on treatment and prognosis for patients with particular genetic subtypes of diabetes. The genetic basis of type 2 diabetes, however, remained elusive.

In recent years, the field of human genetics discovery has been revolutionised by publically funded initiatives such as the Human Genome Project, HapMap and 1000 Genomes projects. These, in tandem with technological advances such as array genotyping and next-generation sequencing, have enabled genome-wide studies of genetic variation in previously unimaginable sample numbers. This has in turn led to an explosion in the number of genetic loci robustly implicated in type 2 diabetes risk.

In writing this book, we have called upon a number of our colleagues who, over the years, have been part of highly collaborative international efforts to advance our understanding of the genetic basis of type 2 diabetes and related traits. We are indebted to them for agreeing to help us with capturing this journey. They have described the huge progress that has been made, whilst at the same time outlining the substantial challenges that lie ahead if we are to fully capitalise on the these discoveries and translate our improved understanding of the genetic basis of type 2 diabetes into advances in clinical care.

Anna L. Gloyn, Oxford
Mark I. McCarthy, Oxford

